



Ms. Ziva Mesika appointed as Head of Regulatory Affairs Group

14th June 2007: Announcement from the office of the Chairman and CEO.

I am pleased to announce the appointment of Ms. Ziva Mesika, formerly head of RA in Israel, as Head of the Regulatory Affairs Group (RA) effective June 16th, 2007. Ms. Mesika will be based at SciGen Israel.

Ms. Mesika came to us from Serono where she gained considerable RA experience in the Biotechnology Sector and significant exposure to health regulatory agencies in Europe, the USA and Israel. Ms. Mesika was instrumental in the worldwide approval of BetaSeron, Serono's Beta Interferon.

In her capacity as Head of RA, Ms. Mesika will be responsible for all regulatory departments within the SciGen Group liaising with our licensors, suppliers and R & D partners on RA matters. Ms. Mesika will be a member of the Executive Committee reporting to the CEO on all aspects of RA and to the Sr. VP of Operations on matters related to operations and Israel regulatory functions.

Dr. Rachel Adams, the present Head of Global Regulatory Affairs, who was serving both Bioton and SciGen and based in the UK has resigned her position effective June 16th, 2007.

About SciGen:

SciGen Ltd is a biopharmaceutical company involved in commercializing later stage research. It co-develops and markets biopharmaceutical products for human healthcare. SciGen focuses in the areas of gastroenterology, endocrinology and immunology. Its product portfolio includes vaccines and therapeutics.

SciGen acquires rights to manufacture, distribute and market biopharmaceutical products under exclusive licensing arrangements. SciGen's portfolio currently includes proprietary biotechnology-derived products, and Biosimilar products, which allow for faster entry into the market, as Biosimilar products have undergone much of the clinical development and trials required to bring drugs to market. This minimizes the risks associated with early stage product development. SciGen currently undertakes R&D activities in collaboration with strategic partners and institutions.

SciGen's competitive advantage is in identifying research with commercial potential at an early stage to which it adds its expertise in clinical development, gaining regulatory approval and bringing products to market.



SciGen is a Singaporean biotechnology company, established in 1988 and listed on the Australian Stock Exchange (ASX code SIE). SciGen is headquartered in Singapore, with subsidiary companies in the USA, Australia, S. Korea, Hong Kong, Philippines, Vietnam, Israel and India, a Joint Venture in China, commercial partners in Europe and collaborative partners in the USA and the Netherlands

Further information:

Company – Investor Relations	Company
Ms. Maria Arroyan SciGen Australia +61 2 9234 1700 email: mariaaroyan@scigen.com.au	Saul Mashaal Chairman, Founder & CEO SciGen Ltd. + 61 2 9485 1800 +65 9630 5691 (Mobile)